Rational design strategies for FimH antagonists: new drugs on the horizon for urinary tract infection and Crohn's disease.

@article{MydockMcGrane2017RationalDS,
  title={Rational design strategies for FimH antagonists: new drugs on the horizon for urinary tract infection and Crohn's disease.},
  author={Laurel Mydock-McGrane and Thomas J Hannan and James W Janetka},
  journal={Expert opinion on drug discovery},
  year={2017},
  volume={12 7},
  pages={
          711-731
        }
}
INTRODUCTION The bacterial adhesin FimH is a virulence factor and an attractive therapeutic target for urinary tract infection (UTI) and Crohn's Disease (CD). Located on type 1 pili of uropathogenic E. coli (UPEC), the FimH adhesin plays an integral role in the pathogenesis of UPEC. Recent efforts have culminated in the development of small-molecule mannoside FimH antagonists that target the mannose-binding lectin domain of FimH, inhibiting its function and preventing UPEC from binding… CONTINUE READING
Related Discussions
This paper has been referenced on Twitter 4 times. VIEW TWEETS

References

Publications referenced by this paper.
Showing 1-10 of 98 references

Nice review of multivalent ligands of FimH and other bacterial lectins

S Cecioni, A Imberty, S. Vidal
Trends Biotechnol • 2016

Prodruggability of carbohydrates — oral FimH antagonists

W Schönemann, S Kleeb, P Dätwyler
Can J Chem • 2016

Similar Papers

Loading similar papers…